BigHat Biosciences Raises $75 Million in Series C Funding
BigHat Biosciences, based in San Mateo, California, has successfully closed a $75 million Series C funding round. The round was led by DFJ Growth and Premji Invest, with participation from an array of investors including Catalio Capital Management, LG Technology Ventures, Sigmas Group, 8VC, Alexandria Venture Investments, Amgen Ventures, Andreessen Horowitz, Discovery Ventures, GRIDS Capital, Intermountain Ventures, Eli Lilly, Merck Global Health Innovation Fund, Quadrille Capital, and Section 32.
BigHat Biosciences is known for its innovative approach to antibody discovery, utilizing a machine learning-driven platform to streamline the design, optimization, and production of antibodies.
Leadership and Vision
Peyton Greenside, Co-founder and CEO of BigHat Biosciences, has been instrumental in steering the company towards its current trajectory. Greenside emphasized the importance of this funding round in enhancing the company's capabilities and expanding its platform.
Allocation of Funds
While specific details regarding the allocation of the funds were not disclosed, it is anticipated that the capital will be used to further develop BigHat's technology and expand its market reach. The investment will likely support scaling operations and accelerating the pace of research and development.
Investor Confidence
The participation of prominent investors like DFJ Growth and Premji Invest underscores the growing confidence in BigHat Biosciences' potential to revolutionize the field of antibody therapeutics. The diverse group of investors reflects a broad interest in the company's approach to addressing critical challenges in drug discovery.
BigHat's innovative platform continues to attract significant attention and investment, positioning the company well for future growth and development in the biotechnology sector.